← 治験一覧に戻る
NIZ985単独およびスパルタリズマブとの併用による第I/Ib相試験
基本情報
- NCT ID
- NCT04261439
- ステータス
- 中止
- 試験のフェーズ
- 第1相
- 試験タイプ
- 介入
- 目標被験者数
- 60
- 治験依頼者名
- Novartis
概要
The purpose of this phase I/Ib study was to determine the safety profile of NIZ985 (new formulation), and if it could be safely combined with spartalizumab or tislelizumab and to determine the appropriate dose and schedule for further study. Moreover, the study characterized the pharmacokinetic profiles of NIZ985 as a single agent and in combination with spartalizumab or tislelizumab and identified preliminary anti-tumor activity.
対象疾患
In Escalation: All Patients With Solid Tumors and LymphomaIn Expansion: Melanoma, Non-small Cell Lung Cancer
介入
NIZ985(DRUG)
Spartalizumab(DRUG)
Tislelizumab(DRUG)
依頼者（Sponsor）
ノバルティスファーマ株式会社(INDUSTRY)